Alnylam Pharmaceuticals delivered robust Q2 2024 financial results with global net product revenues reaching $410 million, representing 34% YoY growth. The performance was primarily driven by its TTR franchise, which grew 37% YoY to $307 million, with AMVUTTRA contributing $230 million. GIVLAARI and OXLUMO generated combined revenues of $103 million, up 25% YoY.The company reported positive topline results from the HELIOS-B Phase 3 study of vutrisiran in ATTR cardiomyopathy patients, demonstrating 28% reduction in composite cardiovascular events and 36% reduction in all-cause mortality. Based on these results, Alnylam plans to submit a supplemental New Drug Application using a Priority Review Voucher.Given the strong performance, Alnylam raised its 2024 financial guidance, increasing combined net product revenue forecast to $1,575-1,650 million from $1,400-1,500 million previously. The company also updated its net revenues from collaborations guidance to $575-650 million, reflecting recent modifications to its Regeneron collaboration agreement.

Alnylam Pharmaceuticals delivered robust Q2 2024 financial results with global net product revenues reaching $410 million, representing 34% YoY growth. The performance was primarily driven by its TTR franchise, which grew 37% YoY to $307 million, with AMVUTTRA contributing $230 million. GIVLAARI and OXLUMO generated combined revenues of $103 million, up 25% YoY.The company reported positive topline results from the HELIOS-B Phase 3 study of vutrisiran in ATTR cardiomyopathy patients, demonstrating 28% reduction in composite cardiovascular events and 36% reduction in all-cause mortality. Based on these results, Alnylam plans to submit a supplemental New Drug Application using a Priority Review Voucher.Given the strong performance, Alnylam raised its 2024 financial guidance, increasing combined net product revenue forecast to $1,575-1,650 million from $1,400-1,500 million previously. The company also updated its net revenues from collaborations guidance to $575-650 million, reflecting recent modifications to its Regeneron collaboration agreement.